GlassScriptPhysician profile
Victor Harrell
NPI 1922409002
$11,035.65
in general payments reported to CMS, 2019-2025
36 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,732 · 2022: $3,070 · 2023: $2,162 · 2024: $2,858 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,233.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,355.21 | 2021-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $3,034.47 | 2021-2025 | Sunlenca, Descovy, Biktarvy |
| Merck Sharp & Dohme LLC | $537.98 | 2021-2025 | Pifeltro, Delstrigo |
| Otsuka America Pharmaceutical, INC. | $408.50 | 2022-2024 | Rexulti |
| Novo Nordisk INC | $396.53 | 2021-2024 | Wegovy, Saxenda |
| Janssen Biotech, INC. | $372.32 | 2021-2023 | Symtuza |
| Janssen Products, LP | $345.89 | 2022-2023 | Symtuza |
| Janssen Pharmaceuticals, INC | $269.94 | 2023-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $265.06 | 2024-2025 | Caplyta |
| Theratechnologies INC. | $203.91 | 2022-2025 | Trogarzo, Egrifta |
| Abbvie INC. | $198.85 | 2021-2024 | |
| Lundbeck LLC | $191.34 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $188.03 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $166.02 | 2021-2022 | |
| Napo Pharmaceuticals INC | $122.17 | 2021-2023 | Mytesi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $121.83 | 2022 | |
| Lilly USA, LLC | $99.08 | 2021-2024 | Mounjaro |
| Shionogi INC | $98.35 | 2024-2025 | Fetroja |
| Bayer Healthcare Pharmaceuticals INC. | $97.02 | 2022 | |
| Exact Sciences Corporation | $72.93 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $69.81 | 2021 | |
| Genentech USA, INC. | $62.71 | 2021-2022 | |
| Emd Serono, INC. | $47.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.42 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.42 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $25.62 | 2021 | |
| Janssen Scientific Affairs, LLC | $25.02 | 2023 | Symtuza |
| Melinta Therapeutics, LLC | $24.35 | 2024 | Rezzayo, Kimyrsa |
| Boston Scientific Corporation | $21.14 | 2024 | Wavewriter Alpha Prime 16 |
| Clarus Therapeutics INC. | $18.90 | 2021 | |
| Antares Pharma, INC. | $18.87 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.79 | 2022 | |
| Seqirus USA INC | $14.01 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.68 | 2022 | |
| Amgen INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.